Advertisement

Changing Urban–Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014–2017

Published:November 19, 2020DOI:https://doi.org/10.1016/j.amepre.2020.08.031

      Introduction

      The advent of direct-acting antiviral agents for treating hepatitis C virus infection has made hepatitis C virus elimination possible. Rural patients with hepatitis C virus infection may be less likely to access direct-acting antiviral agents, but the real-world evidence is scarce on urban–rural disparities in direct-acting antiviral agent utilization.

      Methods

      This retrospective cohort study was conducted in 2019–2020 using Medicare data to examine urban–rural disparities in direct-acting antiviral agent utilization among newly diagnosed patients with hepatitis C virus infection in 2014–2016. Direct-acting antiviral agent use was defined as filling ≥1 prescription for direct-acting antiviral agents during 2014–2017, and patient's urban–rural status was classified on the basis of their ZIP code of residence. This study evaluated the associations between multilevel factors and direct-acting antiviral agent use with a focus on urban–rural disparities. It also assessed changes over time in urban–rural disparities in direct-acting antiviral agent utilization using multivariable cause-specific Cox regression analyses with time-varying hazard ratios.

      Results

      Among 204,018 new patients with hepatitis C virus infection, about 30% received direct-acting antiviral agents during 2014–2017. Cumulative direct-acting antiviral agent use gradually increased over time in both urban and rural patients. However, the increase was greater in urban patients than in rural patients. In the first year of follow-up, rural patients had a similar rate of receiving direct-acting antiviral agents (adjusted hazard ratio=1.03, 95% CI=1.00, 1.07), but they were less likely to use direct-acting antiviral agents in later years than urban patients (adjusted hazard ratio=0.85, 95% CI=0.81, 0.90 in the second year, adjusted hazard ratio=0.82, 95% CI=0.76, 0.89 in the third year, and adjusted hazard ratio=0.76, 95% CI=0.64, 0.90 in the fourth year of follow-up).

      Conclusions

      This study reveals important gaps in hepatitis C virus treatment and suggests increasing urban–rural disparities in direct-acting antiviral agent utilization. Enhancing direct-acting antiviral agent uptake in rural populations with hepatitis C virus infection will help reduce hepatitis C virus‒related health disparities and reach the national goal of eliminating hepatitis C virus infection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Ly KN
        • Xing J
        • Klevens RM
        • Jiles RB
        • Ward JW
        • Holmberg SD
        The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 [published correction appears in Ann Intern Med. 2012;156(11):840].
        Ann Intern Med. 2012; 156: 271-278https://doi.org/10.7326/0003-4819-156-4-201202210-00004
        • Younossi Z
        • Park H
        • Henry L
        • Adeyemi A
        • Stepanova M
        Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden.
        Gastroenterology. 2016; 150: 1599-1608https://doi.org/10.1053/j.gastro.2016.02.039
        • Hofmeister MG
        • Rosenthal EM
        • Barker LK
        • et al.
        Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016.
        Hepatology. 2019; 69: 1020-1031https://doi.org/10.1002/hep.30297
        • Smith BD
        • Morgan RL
        • Beckett GA
        • et al.
        Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 [published correction appears in MMWR Recomm Rep. 2012;61(43):886].
        MMWR Recomm Rep. 2012; 61: 1-32
        • D'Ambrosio R
        • Degasperi E
        • Colombo M
        • Aghemo A
        Direct-acting antivirals: the endgame for hepatitis C?.
        Curr Opin Virol. 2017; 24: 31-37https://doi.org/10.1016/j.coviro.2017.03.017
      1. WHO. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Geneva, Switzerland: WHO.https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/. Published May 2016. Accessed 13 September 2019.

        • AASLD/IDSA HCV Guidance Panel
        Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
        Hepatology. 2015; 62: 932-954https://doi.org/10.1002/hep.27950
      2. Patients with HIV/HCV coinfection. American Association for the Liver Diseases, Infectious Diseases Society of America.https://www.hcvguidelines.org/unique-populations/hiv-hcv. Updated August 27, 2020. Accessed April 23, 2019.

      3. HHS. National viral hepatitis action plan 2017–2020. Washington, DC: HHS https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf. Published January. Accessed December 12, 2019.

        • Jung JK
        • Feldman R
        • Cheong C
        • Du P
        • Leslie D
        Coverage for hepatitis C drugs in Medicare part D.
        Am J Manag Care. 2016; 22: SP220-SP226
        • Lynch SM
        • Wu GY
        Hepatitis C virus: a review of treatment guidelines, cost-effectiveness, and access to therapy.
        J Clin Transl Hepatol. 2016; 4: 310-319https://doi.org/10.14218/JCTH.2016.00027
        • Marcus JL
        • Hurley LB
        • Chamberland S
        • et al.
        Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population.
        Public Health Rep. 2018; 133: 452-460https://doi.org/10.1177/0033354918772059
        • Spradling PR
        • Xing J
        • Rupp LB
        • et al.
        Uptake of and factors associated with direct-acting antiviral therapy among patients in the Chronic Hepatitis Cohort Study, 2014 to 2015.
        J Clin Gastroenterol. 2018; 52: 641-647https://doi.org/10.1097/MCG.0000000000000857
        • Njei B
        • Esserman D
        • Krishnan S
        • et al.
        Regional and rural-urban differences in the use of direct-acting antiviral agents for hepatitis C virus: the Veteran Birth Cohort.
        Med Care. 2019; 57: 279-285https://doi.org/10.1097/MLR.0000000000001071
        • Jung J
        • Du P
        • Feldman R
        • Kong L
        • Riley 3rd, T
        Racial/ethnic and socioeconomic disparities in use of direct-acting antivirals among Medicare beneficiaries with chronic hepatitis C, 2014-2016.
        J Manag Care Spec Pharm. 2019; 25: 1236-1242https://doi.org/10.18553/jmcp.2019.25.11.1236
        • Davis GL
        • Alter MJ
        • El-Serag H
        • Poynard T
        • Jennings LW
        Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.
        Gastroenterology. 2010; 138 (e5216): 513-521https://doi.org/10.1053/j.gastro.2009.09.067
        • Maor Y
        • Malnick SD
        • Melzer E
        • Leshno M
        Treatment of chronic hepatitis C in the aged - does it impact life expectancy? A decision analysis.
        PLoS One. 2016; 11e0157832https://doi.org/10.1371/journal.pone.0157832
        • Rongey C
        • Shen H
        • Hamilton N
        • Backus LI
        • Asch SM
        • Knight S
        Impact of rural residence and health system structure on quality of liver care.
        PLoS One. 2013; 8: e84826https://doi.org/10.1371/journal.pone.0084826
        • Chirikov VV
        • Shaya FT
        • Howell CD
        Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients.
        Hepatology. 2015; 62: 68-78https://doi.org/10.1002/hep.27775
        • Westergaard RP
        • Stockman LJ
        • Hyland HA
        • Guilfoyle SM
        • Fangman JJ
        • Vergeront JM
        Provider workforce assessment in a rural hepatitis C epidemic: implications for scale-up of antiviral therapy.
        J Prim Care Community Health. 2015; 6: 215-217https://doi.org/10.1177/2150131914560229
        • Rogal SS
        • McCarthy R
        • Reid A
        • et al.
        Primary care and hepatology provider-perceived barriers to and facilitators of hepatitis C treatment candidacy and adherence.
        Dig Dis Sci. 2017; 62: 1933-1943https://doi.org/10.1007/s10620-017-4608-9
        • Gordon SC
        Hepatitis C virus detection and treatment in rural communities.
        Gastroenterol Hepatol (N Y). 2018; 14: 720-722
        • Schranz AJ
        • Barrett J
        • Hurt CB
        • Malvestutto C
        • Miller WC
        Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C.
        Curr HIV/AIDS Rep. 2018; 15: 245-254https://doi.org/10.1007/s11904-018-0393-0
        • Gowda C
        • Lo Re 3rd, V
        Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.
        Curr Hepatol Rep. 2018; 17: 111-120https://doi.org/10.1007/s11901-018-0394-x
        • Kapadia SN
        • Marks KM
        Hepatitis C management simplification from test to cure: a framework for primary care providers.
        Clin Ther. 2018; 40: 1234-1245https://doi.org/10.1016/j.clinthera.2018.05.010
        • Arora S
        • Kalishman S
        • Thornton K
        • et al.
        Expanding access to hepatitis C virus treatment–extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care.
        Hepatology. 2010; 52: 1124-1133https://doi.org/10.1002/hep.23802
        • Arora S
        • Thornton K
        • Murata G
        • et al.
        Outcomes of treatment for hepatitis C virus infection by primary care providers.
        N Engl J Med. 2011; 364: 2199-2207https://doi.org/10.1056/NEJMoa1009370
        • Jayasekera CR
        • Arora S
        • Ahmed A
        Hepatitis C treatment delivery mandates optimizing available health care human resources: a case for task shifting.
        JAMA. 2016; 315: 1947-1948https://doi.org/10.1001/jama.2016.1993
        • Dunn EE
        • Vranek K
        • Hynicka LM
        • Gripshover J
        • Potosky D
        • Mattingly 2nd, TJ
        Evaluating a collaborative approach to improve prior authorization efficiency in the treatment of hepatitis C virus.
        Qual Manag Health Care. 2017; 26: 136-139https://doi.org/10.1097/QMH.0000000000000137
        • Yoo ER
        • Perumpail RB
        • Cholankeril G
        • Jayasekera CR
        • Ahmed A
        Expanding treatment access for chronic hepatitis C with task-shifting in the era of direct-acting antivirals.
        J Clin Transl Hepatol. 2017; 5: 130-133https://doi.org/10.14218/JCTH.2016.00059
        • Juneja M
        • Euliano R
        • Satoskar R
        • Lewis JH
        Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis.
        Dig Dis Sci. 2013; 58: 3348-3358https://doi.org/10.1007/s10620-013-2812-9
        • Aitken M
        • Kleinrock M
        • Pennente K
        • Lyle J
        • Nass D
        • Caskey L
        Medicines use and spending in the U.S.: a review of 2016 and outlook to 2021.
        QuintilesIMS Institute, Parsippany, NJ2017 (Published May)
        • McBride TD
        • Mueller KJ
        Effect of Medicare payment on rural health care systems.
        J Rural Health. 2002; 18: 147-163https://doi.org/10.1111/j.1748-0361.2002.tb00927.x
        • Gowda C
        • Lott S
        • Grigorian M
        • et al.
        Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a national specialty pharmacy cohort study.
        Open Forum Infect Dis. 2018; 5: ofy076https://doi.org/10.1093/ofid/ofy076
        • Lo Re 3rd, V
        • Gowda C
        • Urick PN
        • et al.
        Disparities in absolute denial of modern hepatitis C therapy by type of insurance.
        Clin Gastroenterol Hepatol. 2016; 14: 1035-1043https://doi.org/10.1016/j.cgh.2016.03.040
        • Centers for Medicare & Medicaid Services
        CCW chronic condition algorithms.
        2019 (Published)
        • van Boemmel-Wegmann S
        • Lo Re 3rd, V
        • Park H
        Early treatment uptake and cost burden of hepatitis C therapies among newly diagnosed hepatitis C patients with a particular focus on HIV coinfection.
        Dig Dis Sci. 2020; 65: 3159-3174https://doi.org/10.1007/s10620-019-06037-z
        • Area health resources files
        HHS, Health Resources and Services Administration, Bureau of Health Workforce.
        2019 (Updated July 31)
        • RUCA data
        WWAMI, RUCA, Rural Health Research Center.
        2007 (Updated November 13)
        • European Association for the Study of the Liver
        EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [published correction appears in J Hepatol. 2018;69(5):1207].
        J Hepatol. 2018; 69: 406-460https://doi.org/10.1016/j.jhep.2018.03.024
        • Charlson ME
        • Pompei P
        • Ales KL
        • MacKenzie CR
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383https://doi.org/10.1016/0021-9681(87)90171-8
        • Gray RJ
        A class of K-sample tests for comparing the cumulative incidence of a competing risk.
        Ann Statist. 1988; 16: 1141-1154https://doi.org/10.1214/aos/1176350951
        • Lau B
        • Cole SR
        • Gange SJ
        Competing risk regression models for epidemiologic data.
        Am J Epidemiol. 2009; 170: 244-256https://doi.org/10.1093/aje/kwp107
        • Asher AK
        • Portillo CJ
        • Cooper BA
        • Dawson-Rose C
        • Vlahov D
        • Page KA
        Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs.
        Subst Use Misuse. 2016; 51: 1218-1223https://doi.org/10.3109/10826084.2016.1161054
        • Stearns SC
        • Slifkin RT
        • Edin HM
        Access to care for rural Medicare beneficiaries.
        J Rural Health. 2000; 16: 31-42https://doi.org/10.1111/j.1748-0361.2000.tb00434.x
        • Laraque F
        • Varma JK
        A public health approach to hepatitis C in an urban setting.
        Am J Public Health. 2017; 107: 922-926https://doi.org/10.2105/AJPH.2017.303718
        • Vu TM
        • Toribio W
        • Riazi F
        • et al.
        Increasing access to hepatitis C virus medications: a program model using patient navigators and specialty pharmacy to obtain prior authorization approval.
        J Manag Care Spec Pharm. 2018; 24: 329-333https://doi.org/10.18553/jmcp.2018.24.4.329
        • Suryaprasad AG
        • White JZ
        • Xu F
        • et al.
        Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.
        Clin Infect Dis. 2014; 59: 1411-1419https://doi.org/10.1093/cid/ciu643
        • Dahari H
        • Boodram B
        How to eliminate HCV in people who inject drugs in the USA.
        Lancet Infect Dis. 2018; 18: 134-135https://doi.org/10.1016/S1473-3099(17)30678-3